Therapeutic maintenance level of methotrexate in rheumatoid arthritis;Taux de maintenance thérapeutique: À propos du méthotrexate au cours de la polyarthrite rhumatoïde traitée au Maroc

Cahiers Sante

Volumn 16, Issue 3, 2006, Pages 167-172

  Tahiri, Latifa ^a   Allali, Fadoua ^a,b   Jroundi, Imane ^b   Abouqal, Radouane ^b   Hajjaj Hassouni, Najia ^a  

^a Hopital El Ayachi   (Morocco)

^b MOHAMMED V UNIVERSITY   (Morocco)

Author keywords

Morocco; Polyarthritis; Rheumatology; Therapy

Indexed keywords

ANTIRHEUMATIC AGENT; CREATININE; METHOTREXATE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; ATTITUDE TO HEALTH; BLOOD; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MOROCCO; PATIENT; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATTITUDE TO HEALTH; COHORT STUDIES; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTE COUNT; MALE; METHOTREXATE; MIDDLE AGED; MOROCCO; PATIENT DROPOUTS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 33847065017     PISSN: 11575999     EISSN: None     Source Type: Journal    
DOI: 10.1684/san.2006.0030     Document Type: Article

References (23)

1. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004 ; 50 : 1370-82.
2. Anaya JM, Jorgensen C, Daures JP, Combe B, Sany J. Taux de maintenance thérapeutique du Methotrexate au cours de la polyarthrite rhumatoïde. Rev Rhum 1992 ; 52 : 181-7.
3. Berthelot JM, Combe B. Efficacité, tolérance et maintien du Methotrexate dans le traitement des polyarthrites rhumatoïdes. Rev Rhum 2002 ; 6 : 72-83.
4. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 ; 31 : 315-24.
5. Steinbrocker O, Traeger GH, Batterman RC. Therapeutic criteria in rheumatoïd arthritis. JAMA 1949 ; 140 : 659-62.
6. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995 ; 38 : 727-35.
7. Pinals RS, Masi AT, Larsen RA, and the subcommitte for criteria of remission in rheumatoid arthritis of the American Rheumatism Association-Diagnostic and therapeutic committee criteria. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981 ; 24 : 1308-15.
8. Dougados M, Nguyen M, Duchenne L, Benjelloun M, Amor B. Appréciation de l'utilité des traitements de fond de la polyarthrite rhumatoïde par l'analyse du taux de maintenance thérapeutique. Rev Rhum 1989 ; 56 : 89-92.
9. Pavelka K, Forejtova S, Pavelkova A, Zvarova J, Rovensky J, Tuchynova A. Analysis of the reasons for DMARD therapy discontinuation in patients with Rheumatoid Arthritis in the czech and Slovak republics. Clin Rheumatol 2002 ; 21 : 220-36.
10. Sany J. Polyarthrite rhumatoïde de l'adulte. Paris : John Libbey Eurotext, 2003.
11. Wluka A, Buchbinder R, Mylvaganam A, et al. Longterm Methotrexate use in Rheumatoid Arthritis : 12 year follow up of 460 patients treated in community practice. J Rheumatol 2000 : 27 : 1864-71.
12. Rau R, Schleusser B, Herborn G, Karger T. Longterrn treatment of destructive Rheumatoid Arthritis with Méthotrexate. J Rheumatol 1997 ; 24 : 1881-9.
13. Pincus T, Marcum SB, Callahan LF. Long term drug therapy for rheumatoid arthritis in seven rheumatology private practices : II. Second line drugs and prednisone. J Rheumatol 1992 ; 19 : 1885-94.
14. Cush JJ, Kavanaugh AF, Lipsky PE, Arthritis Care Algorithm Steering Committee. 1995 national survey of US rheurnatologists : beliefs and practices regarding therapy, referrals, managed care, guidelines and algorithms [abstract]. Arthritis Rheum 1996 ; 39 (Suppl 9) : S16.
15. Rau R, Herborn G. Benefit and risk of methotrexate treatment in rheumatoid arthritis. Clin Exp Rheumatol 2004 ; 22(5 Suppl 35) : S83-S94.
16. Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis, Ann Rheum Dis 2004 ; 63 : 1232-4.
17. Sany J. Traitement de la Polyarthrite Rhumatoïde par le méthotrexate. Rev de Rhum Isupplpédagogique) 1997 ; 64 : 193-207.
18. Weinblatt ME, Kaplan H, Germain BF, et al. Méthotrexate in Rheumatoid Arthritis. A five year prospective multicenter study. Arthritis Rheum 1994 ; 37 : 1492-8.
19. Alarcon GS, Tracy IC, Strand GM, Singh K, Macaluso M. Survival and drug discontinuation analyses in a large cohort of Methotrexate treated Rheumatoid Arthritis patients. Ann Rheum Dis 1995 ; 54 : 708-12.
20. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate : a 3-year prospective study in France. Blood 2002 ; 99 : 3909-15.
21. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996; 14: 194-9.
22. Hajjaj-Hassouni N, Hassouni F, Guedira N, Lazrak N. La Polyarthrite rhumatoïde au Maroc. A propos de 444 cas. Sem Hop Paris 1994 ; 70 : 12-20.
23. Fürst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA. Adverse experience with Methotrexate during 176 weeks of a long-term prospective trial in patients with Rheumatoid Arthritis. J Rheumatol 1990 ; 17 : 1658-735.